Experienced in Prothrombin Deficiency

Dr. Michael W. Meshad

Southern Cancer Center PC
Mobile, AL
Experienced
in Prothrombin Deficiency
Specialties:Hematology Oncology | Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Michael Meshad is a Hematologist Oncology specialist and an Oncologist in Mobile, Alabama. Dr. Meshad and is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Paget Disease of the Breast, Non-Hodgkin Lymphoma, Lung Cancer, Familial Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Meshad is currently accepting new patients in some locations.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in AL
Hospital Affiliations
Springhill Medical Center
Mobile Infirmary Medical Center
Jackson Medical Center
Thomas Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

SOUTHERN CANCER CENTER PC
3719 Dauphin St, Suite 5, Mobile, AL 36608
251-625-6896
Other Locations
SOUTHERN CANCER CENTER PC
29653 Anchor Cross Blvd, Daphne, AL 36526
251-625-6896
SOUTHERN CANCER CENTER PC
1703 N Bunner St, Foley, AL 36535
251-625-6896
SOUTHERN CANCER CENTER PC
6701 Airport Blvd, Mobile, AL 36608
251-625-6896
SOUTHERN CANCER CENTER PC
220 Hospital Dr, Jackson, AL 36545
251-625-6896

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Active_not_recruiting
Publish Date: September 13, 2023
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Enrollment Status: Terminated
Publish Date: March 13, 2023
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 13 Less Clinical Trials

1 Total Publications

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Journal: Journal of the advanced practitioner in oncology
Published: January 13, 2025
Similar Doctors
Expertise in
130
conditions
Dr. Allison P. Wall
Hematology Oncology | Hematology | Oncology
Expertise in
130
conditions
Dr. Allison P. Wall
Hematology Oncology | Hematology | Oncology

Memorial Hospital At Gulfport

920 Tommy Munro Dr, Suite 100, 
Biloxi, MS 
 (50.9 mi)
228-575-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Allison Wall is a Hematologist Oncology specialist and a Hematologist in Biloxi, Mississippi. Dr. Wall and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Appendix Cancer, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Paget Disease of the Breast, and Neuroendocrine Tumor. Dr. Wall is currently accepting new patients.

Expertise in
72
conditions
Dr. Ranjith Dissanayake
Hematology Oncology | Hematology | Oncology
Expertise in
72
conditions
Dr. Ranjith Dissanayake
Hematology Oncology | Hematology | Oncology

Sacred Heart Health System Inc

4501 N Davis Hwy, Suite C, 
Pensacola, FL 
 (56.1 mi)
850-416-4960
Languages Spoken:
English
See accepted insurances

Ranjith Dissanayake is a Hematologist Oncology specialist and a Hematologist in Pensacola, Florida. Dr. Dissanayake and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Thrombocytopenia, Paget Disease of the Breast, and Bone Marrow Aspiration.

Expertise in
17
conditions
Dr. Brian J. Heller
Hematology Oncology | Oncology
Expertise in
17
conditions
Dr. Brian J. Heller
Hematology Oncology | Oncology

Southern Cancer Center PC

3719 Dauphin St, Suite 102, 
Mobile, AL 
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Heller is a Hematologist Oncology specialist and an Oncologist in Mobile, Alabama. Dr. Heller and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Heller is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile